Teledyne Technologies has begun manufacturing infrared focal‑plane modules for the Space Development Agency’s (SDA) Tracking Layer Tranche 3 program, a key component of the Proliferated Warfighter Space Architecture that provides global missile‑warning and tracking capabilities in low‑Earth orbit.
The company is supplying radiation‑hardened, multi‑megapixel detectors to the prime contractors that received the $3.5 billion Tranche 3 award—Lockheed Martin, Rocket Lab USA, Northrop Grumman and L3Harris Technologies. While Teledyne’s specific contract value is not disclosed, the work is part of a multi‑year, recurring revenue stream that will support the production of dozens of satellites scheduled for fiscal year 2029.
Teledyne’s modules will be integrated into the satellites’ tracking layers, enabling the constellation to detect, track and respond to missile threats in real time. The production start signals Teledyne’s ability to scale complex, high‑reliability components for a proliferated space architecture that relies on rapid, repeatable manufacturing.
The contract win follows Teledyne’s Q4 2025 earnings beat, where revenue reached $1.61 billion and diluted EPS was $6.30—above estimates of $5.83. The new SDA work adds a stable, long‑term revenue source that complements the company’s broader growth strategy in advanced imaging and sensor solutions for national‑security customers.
Management highlighted the partnership’s continuity, noting that Teledyne has supplied components for SDA Tranches 0, 1 and 2 and that the Tranche 3 win “strengthens the nation’s space‑based sensing and surveillance capabilities.” The contract underscores Teledyne’s strategic focus on space‑based defense and its capacity to deliver cutting‑edge technology to a high‑profile, government‑driven program.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.